Randomized Phase II Study of Docetaxel Followed by Vandetanib (ZD6474) vs. Docetaxel Plus Vandetanib in Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 21 Dec 2016
At a glance
- Drugs Docetaxel (Primary) ; Vandetanib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 04 Apr 2014 Status changed from active, no longer recruiting to completed, according to publication of results.
- 04 Apr 2014 Results published in the European Journal of Cancer.
- 06 Jun 2012 Planned end date changed from 1 Oct 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.